Keywords
How to Cite
Abstract
ABSTRACT
Purpose: To report the case of a patient with multiple sclerosis who underwent treatment with Natalizumab for two years, and then switched to Ocrelizumab. Case details: Patient, JFA, 29 years old, married, came to the Medical Service with sudden neurological changes, reduced unilateral visual acuity and diplopia. Therefore, a lumbar puncture and magnetic resonance of the skull were made, which demonstrated oligoclonal bands and demyelinating lesions, respectively, which enabled diagnosis of multiple sclerosis. Thus, pulse therapy was started, and after controlling the outbreak, the patient started monthly treatment with the immunomodulatory drug Natalizumab. However, after two years of treatment, a change was made to another immunomodulatory drug, Ocrelizumab, as the treatment reached the time defined by the National Supplementary Health Agency, in addition to the fact that the patient tested positive for the JC virus. Final considerations: Multiple sclerosis is a neurodegenerative disease which is difficult to treat, because numberless biases are considered when starting a drug, such as the classification of the disease. Thus, in the relapsing-remitting form, the change from Natalizumab to Ocrelizumab in a patient unable to use Natalizumab, proved to be positive, because he did not present new outbreaks after the drug was changed.
References
SHON, E. H. Diagnóstico de Esclerose Múltipla: Critérios de Diagnóstico McDonald. J Coreano Neurol Assoc, v. 36, n. 4, p. 273-279, 2018.
HEMMER, B. et al. Role of the Innate Adaptive Immune responses in the course of Multiple Sclerosis. The Lancet Neurology, v. 14, n. 4, p. 406-419, 2015.
CARVALHO, L. G. et al. Fatores ambientais envolvidos na Fisiopatologia da Esclerose Múltipla: uma revisão bibliográfica. Brazilian Journal of Health Review, v. 5, n. 1, p. 2793-2808, 2022.
PIGGOTT, T. et al. Multiple Sclerosis International Federation guideline methodology for off-label treatments for multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, v. 7, n. 4, 2021. doi:10.1177/20552173211051855.
COELHO, V. et al. Análise dos aspectos epidemiológicos da Esclerose Múltipla no Brasil durante o período de 2012 a 2022. Brazilian Journal of Health Review, v. 6, n. 6, p. 27513–27527, 2023.
ABREU, E. Sintomas e tratamentos da esclerose múltipla (EM): em busca da qualidade de vida. Revista Acadêmica Oswaldo Cruz, 2019. ISSN 2357-8173.
SILVEIRA, L. et al. Esclerose múltipla: uma abordagem imunológica. Revisão de Literatura. Revista Educação em Saúde, v. 8, n. 2, p. 122-137, 2020.
ANDRADE DE QUEIROZ, G. K. et al. Funcionalidade na Esclerose Múltipla: relato de caso. REVISTA DE SAÚDE - RSF, v. 10, n. 01, 2024. https://doi.org/10.59370/rsf.v10i01.113.
MORALES, R. de R. et al. Qualidade de vida em portadores de esclerose múltipla. Arq Neuro-Psiquiatria, v. 65, n. 2b, p. 454–460, jun. 2007. Disponível em: https://doi.org/10.1590/S0004-282X2007000300018.
SILVA, D. F.; NASCIMENTO, V. M. S. Esclerose múltipla: imunopatologia, diagnóstico e tratamento. Interfaces Científicas - Saúde e Ambiente, Aracaju, v. 2, n. 3, p. 81–90, jun. 2014.
ARAÚJO, D. L. et al. Utilização da ressonância magnética para diagnóstico da esclerose múltipla. Research, Society and Development, v. 9, n. 8, p. e546985936, 2020.
THOMPSON, A. J. et al. Diagnóstico de esclerose múltipla: revisões de 2017 dos critérios McDonald. The Lancet Neurology, v. 17, n. 2, p. 1-10, dez. 2017.
DINIZ, R. S. et al. Esclerose Múltipla: Avanços no Diagnóstico e Tratamento. Brazilian Journal of Implantology and Health Sciences, v. 5, n. 5, p. 188-201, 2023.
ALVES, B. et al. Esclerose múltipla: revisão dos principais tratamentos da doença. Saúde E Meio Ambiente: Revista Interdisciplinar, v. 3, n. 2, p. 19–34, 2015.
FOGARTY, E. et al. Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: systematic review and network meta-analysis. Multiple Sclerosis and Related Disorders, v. 9, p. 23-30, 2016.
RUDICK, R. A. et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. New England Journal of Medicine, v. 354, n. 9, p. 911-923, 2006.
BRASIL. Ministério da Saúde. Portaria Conjunta nº 1, de 07 de Janeiro de 2022. Aprova o Protocolo Clínico e Diretrizes Terapêuticas da Esclerose Múltipla. Diário Oficial da União, Brasília, DF, 17 fev. 2012, seção 1, p. 88.
SILVA, M. C. N. et al. Avaliação da qualidade de vida em portadores de esclerose múltipla: impacto da fadiga, ansiedade e depressão. Fisioterapia e Pesquisa, v. 26, p. 339-345, 2019.
MARQUES, V. et al. Brazilian Consensus for the Treatment of Multiple Sclerosis: Brazilian Academy of Neurology and Brazilian Committee on Treatment and Research in Multiple Sclerosis. Arq Neuropsiquiatr, v. 76, n. 8, p. 539-554, ago. 2018. doi: 10.1590/0004-282X20180078.
ERRANTE, P. et al. Esclerose múltipla: tratamento farmacológico e revisão de literatura. UNILUS Ensino e Pesquisa, v. 13, n. 30, p. 105-117, 2020.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Joubert de Almeida Junior, Saul Girelli Neto, Cris Daiane Nobre Sampaio Chagas, Maria Julia Oliveira Caldeira Horing, Renato Vieira Donzelli, Murilo Alves Coelho Neto, Júlia Emanuelli Seganfredo, Janaína Aparecida Medeiros Manca, Dionísio José Paludo Petek, Willian José Bordin da Silva